Login / Signup

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Sean P KennedyJeremy Z R HanNeil PortmanMax NobisJordan F HastingsKendelle J MurphySharissa L LathamAntonia L CadellDushan MiladinovicGabriella R MarriottYolande E I O'DonnellRobert F ShearerJames T WilliamsAmaya Garcia MunozThomas R CoxD Neil WatkinsDarren N SaundersPaul TimpsonElgene LimWalter KolchDavid R Croucher
Published in: Breast cancer research : BCR (2019)
The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.
Keyphrases
  • immune response
  • tyrosine kinase
  • epidermal growth factor receptor
  • cancer therapy
  • mesenchymal stem cells
  • replacement therapy
  • young adults
  • bone marrow
  • drug delivery
  • breast cancer risk